Product Specific References | - Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS and Too CKL. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol. 2008;179(1):147-51.
- Lunacek A, Schwentner C, Oswald J, Fritsch H, Sergi C, Thomas LN, Rittmaster RS, Klocker H, Neuwirt H, Bartsch G and Radman C. Fetal distribution of 5α-reductase 1 and 5α-reductase 2, and their imput on human prostate development. J Urol. 2007;178(2):716-721.
- Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, OBrien SP and Rittmaster RS. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63(3):231-239.
- Titus MA, Gregory CW, Ford III OH, Schell MJ, Maygarden SJ and Mohler JL. Steroid 5α-reductase isoenzymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005;11(12):4365-4371.
- Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS and Lazier CB. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol.2003:170(5):2019-2025.
|